Dr. Stephen A. Sherwin, MD, is an Independent Director at Epiphany Technology Acquisition Corp., an Independent Director at BioPlus Acquisition Corp., an Advisory partner at Third Rock Ventures LLC, an Independent Director at Biogen, Inc., a Lead Independent Director at Neurocrine Biosciences, Inc., a Clinical Professor at University of California, a Member at American Association for Cancer Research, a Member at American Society of Clinical Oncology and a Professor at The University of California, San Francisco.
He is on the Board of Directors at Epiphany Technology Acquisition Corp., BioPlus Acquisition Corp., Biogen, Inc., Biogen GmbH, Neurocrine Biosciences, Inc. and Rheos Medicines, Inc.
Dr. Sherwin was previously employed as an Independent Director by Neon Therapeutics, Inc., an Independent Director by Aduro BioTech, Inc., an Independent Director by Vical, Inc., an Independent Director by Verastem, Inc., a Chairman-Emeritus by Biotechnology Industry Organization, a Chairman by Ceregene, Inc., an Independent Director by Rigel Pharmaceuticals, Inc., a Chairman & Chief Executive Officer by Cell Genesys, Inc., a Vice President-Clinical Research by Genentech, Inc., a Chairman by Abgenix, Inc., and a Principal by National Cancer Institute.
He also served on the board at BioSante Pharmaceuticals, Inc. and Biogen Idec New Ventures, Inc.
He received his undergraduate degree from Yale University and a doctorate degree from Harvard Medical School.